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Abstract
Background: Dermal wound healing involves a cascade of complex events including angiogenesis and extracellular
matrix remodeling. Several groups have focused in the study of the skin wound healing activity of natural products.
The phytomedicine Acheflan®, and its main active constituent is the oil from Cordia verbenacea which has known
anti-inflammatory, analgesic and antimicrobial activities. To our knowledge, no investigation has evaluated the
effect of Acheflan® in an experimental model of skin wound healing.
The present study has explored the wound healing property of Acheflan® and has compared it with topical
effectiveness of collagenase and fibrinolysin by using Wistar rat cutaneous excision wound model.
Methods: Animals were divided into four groups: untreated animals are negative control (NC), wounds were treated
topically every day with Collagenase ointment (TC), with Fibrinolysin ointment (TF) and with cream Acheflan (TAc). Skin
samples were collected on zero, 8th and 15th days after wounding. The healing was assessed by hematoxylin-eosin (HE),
picrosirius red, hydoxyproline content and immunohistochemical analysis of the vascular endothelial growth factor
(VEGF) and matrix metalloprotease-9 (MMP-9). Statistical analysis was done by ANOVA and Student t-test (p < 0.05).
Results: The histological analysis HE of wound in the TAc group was more efficient because it was possible to observe
the complete remodeling of the epidermis indicating the regression of lesions compared with the NC. The evaluation of
picrosirius staining has demonstrated a significant increase of collagen distribution in the TC and TAc treatments
compared with NC and TF groups. These results are corroborated with hydroxyproline content. Skin TC and TAc
treated rats have showed an increase of VEGF and MMP-9 compared with NC and TF groups. All parameters were
significant (P < 0.05).
Conclusion: The phytomedicine Acheflan® (oil of Cordia verbenacea) and TC possess higher therapeutic properties for
wound healing compared with TF. These ointments seem to accelerate wound healing, probably due to their
involvement with the increase of angiogenesis and dermal remodeling.
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Background
Dermal wound healing is a physiological process involving
several overlapping stages that could include inflamma-
tion, formation of granulation tissue, reepithelialization,
extracellular matrix (ECM) formation and remodeling.
Loss of skin integrity through trauma, injury and chronic
ulcerations may result in homeostasis imbalance and in
significant failure [1]. Wounds are major concerns for the
medical staff and seriously reduce the quality of life of the
patient. Furthermore, skin wound is a public health prob-
lem with high cost and ineffective treatment [2]. Thus, the
attempt to quickly close the skin lesions with ideal func-
tional and aesthetic results would be the goal of clinical
treatment [3].
Nowadays, there has been extensive scientific interest
in pharmacological evaluation on the biological properties
of phytotherapeutics products [4, 5]. In addition, several
studies have focused in evaluating the wound healing
activity of medicinal plants, such as Cleome viscose [6],
Crotalus adamanteus [7], Blumea balsamifera [8], Salvia
miltiorrhiza [9], Bacopa monniera [10],Vitis Vinifera [11]
and Morinda citrifolia [12]. Using an excision wound
model in rat, Nayak and colleagues described that extract
of Punica granatum promotes faster wound healing from
hydroxyproline analysis and histological studies [13]. In
this way, experimental models have been developed and
have significant improved our knowledge of wound repair
because they can be easily accessed to test the efficacy of
different treatments [14, 15].
Cordia verbenacea is a Brazilian plant used to produ-
cing a phytomedicine, which is the main active constitu-
ent of the product Acheflan® developed in Brazil and
approved by ANVISA (Agência Nacional de Vigilância
Sanitária) in 2004 for the management of trauma, tendi-
nopathy and myofacial pain [4]. In Brazil, the companies
need to prove the safety efficacy, quality and safety based
on scientific information of phytomedicines because they
are registered as drugs [16]. Previous phytochemical
study performed with C. verbenacea had demonstrated
the main constituents of the essential oil identified by
gas chromatography/mass spectrometry (GC-MS) (30 %
of α-pinene, 25 % of trans-caryophyllene, 10 % of aloaro-
madendrene and 5 % of α-humulene) [17]. In addition,
Chaves and colleagues [18] quantified by GC-MS the
main active constituent isolated from Acheflan®, the α-
humulene, and 30 min after topical administration of
Acheflan®, the amount of α-humulene absorbed in the
ear of the mice was about 2 μg/ear. Furthermore, it has
been previously reported that the C. verbenacea has
anti-inflammatory, analgesic and antimicrobial activity
[18–24] and low toxicity [19].
To our knowledge, no investigation has evaluated the
effect of Acheflan® in skin injury and our hypothesis was
that its use may accelerate the stages of wound healing
process. Thus, the purpose of this in vivo study was to
evaluate topical effectiveness of Acheflan® on tissue for-
mation, reepithelialization, angiogenesis and, collagen
deposition under cutaneous injury and compared with
traditional agents (collagenase and fibrinolysin).
Methods
Experimental animal model
Sprague–Dawley rats were used in the accomplishment of
the full-thickness excisional wound model using the method
described by [25]. 8 weeks old animals and each weighing
250–300 g were housed individually in individual polyethyl-
ene cages, and were kept at a constant temperature (25 °C)
under a 12-h light/dark cycle with free access to food and
water in the Bioterium of Universidade Estadual da Zona
Oeste – UEZO (Rio de Janeiro, Brazil). The experimental
procedure was approved by the UEZO Institutional Animal
Care and Use Committee (CEUA), protocol code CEUA-
UEZO-002/2013, and all experiments were conducted in
performed with the ethical guidelines from the CEUA.
After the induction of general anesthesia with intra-
peritoneal ketamine (90 mg/kg) and xylazine (10 mg/kg),
the rats’ dorsal regions were shaved and cleaned with
ethanol 70 %. The circular full-thickness excision wound
was made with a biopsy punch of 20 mm in diameter.
The wound was left undressed to the open environment.
Phytomedicine
Acheflan® is a phytomedicine developed in Brazil ap-
proved by the local authority ANVISA, Brazilian FDA-
like agency, at 2004. This product is a topical drug for
the management of trauma, tendinopathy and myofacial
pain developed from the Brazilian medicinal plant Cordia
verbenacea DC (Boraginaceae). Acheflan® cream (TAc)
containing 0.5 % of C. verbenacea essential oil and 2.5 %
of α-humulene provided by Aché Laboratory, Brazil.
Wound model and topical treatment
Immediately after surgical excision the rats were ran-
domly divided into four groups of each six animals: un-
treated animals are negative control (NC), wounds daily
treated topically with Collagenase ointment (TC), wounds
daily treated topically with Fibrinolysin (1 U fibrinolysin,
666 U DNAse and 10 mg chloramphenicol) ointment
(TF) and wounds daily treated topically with phytomedi-
cine cream TAc. The rats were euthanized with overdose
of anesthesia at 8 and 15 days after wounding. The skin
wound samples were collected in each time point: zero
(n = 6), 8 days (n = 3) and 15 days (n = 3). The granulation
tissue formed on the injury was excised leaving a 5 mm
margin of normal skin for histopathological assessment
and determination of hydroyproline.
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Histopathologic analysis
The full thickness wound tissues, including the adja-
cent skin, were fixed immediately in formalin, paraffin-
embedded and cut into 4-μm-thick sections. Part of the
sections were stained with Harris hematoxylin and eosin
(HE), and examined microscopically by two blinded ob-
servers using a 40× objective lens of a light microscope
(Nikon, Tokyo, Japan) connected to a digital camera (Cool-
pix 990; Nikon). To estimate the degrees of wound healing
a histological score was used to determine the dermal and
epidermal regeneration and granulation tissue formation,
as described by Kim and colleagues [26]. Additional sec-
tions were stained with Picrosirius red for observation of
collagen fibers distribution through the calculus of the per-
centage of the marked area in reddish-yellow by field by
using the Image Pro Plus 4.5.1 (Media Cybernetics, Silver
Spring, MD).
Immunohistochemistry and morphometric evaluation
The other paraffin-embedded tissue sections were placed on
silane-treated slides, and maintained at room temperature.
After dewaxing, the sections were treated with a solution of
3 % H2O2 in 0.01 mol/L phosphatebuffer saline (PBS),
pH 7.5, to inhibit endogenous peroxidase activity. The slides
were then immersed in 10 nmol/L citrate buffer (pH 6.0)
and heated in a microwave oven for 5 min to retrieve
masked antigens, to reduce nonspecific antibody binding;
the sections were then incubated with PBS containing a
10 % solution of normal goat serum and 5 % bovine serum
albumin for 30 min. Sections were incubated with the fol-
lowing antibodies: monoclonal antibody against VEGF SC-
7269 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100
dilution and polyclonal antibody against MMP-9 SC-6840
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilu-
tion. Incubations were carried out overnight and then
revealed using LSAB2 Kit HRP, rat (Dako-Cytomation,
Carpinteria, CA) with diaminobenzidine (3,3’-diaminobenzi-
dine tablets; Sigma, St. Louis, MO) as the chromogen and
counterstained with hematoxylin. For each case, negative
control slides consisted of sections incubated with antibody
vehicle or no immune rabbit or mouse serum. Ten fields
of an immunostained section (VEGF and MMP-9) were
chosen at random and captured from each specimen.
Quantification was assessed on captured highquality im-
ages (2048 × 1536 pixels buffer) using the Image Pro Plus
4.5.1 (Media Cybernetics, Silver Spring, MD). Data were
stored in Adobe Photoshop, version 3.0, to enable uneven
illumination and background color to be corrected. Histo-
logic scores (H) for VEGF and MMP-9 were calculated
using the formula H = ΣPi, where i is the intensity ranging
from 0 (negative cells) to 3 (deeply staining cells) and P
is the percentage of staining cells for each given i, with
P values of 1, 2, 3, 4, and 5 indicating <15 %, 15–50 %,
50–85 %, >85 %, and 100 % positive-staining cells,
respectively. The staining result was expressed as mean ±
standard deviations.
Biochemical analyses of the newly formed skins
The hydroxyproline, the basic constituent of collagen,
was taken as a marker of collagen synthesis. The granu-
lation tissue from control and treated groups was dried
at 60–70 °C for 24 h and weighed to determine the dry
granulation tissue weight. Pieces of dried tissue were hy-
drolysed in 6 N HCl at 120 °C for 18 h in sealed tubes.
The hydrolyzed samples were adjusted to pH 7.0 and
were subjected to chloramines-T oxidation for 20 min.
The reaction was terminated by addition of 3.15 M per-
chloric acid and para-dimethylaminobenzaldehyde at 60 °C
to develop a pink color [27]. Absorbance was measured at
557 nm using a spectrophotometer. The procedure was
done in triplicate for all samples, in each time point (zero,
8 and 15 days) and the hydroxyproline content was deter-
mined against a standard curve of hydroxyproline.
Statistical analysis
One-way analysis of variance (ANOVA) was carried out
to identify the differences between treated groups and
controls. Statistical comparisons between variables were
performed with Student t-test. The level of significance for
significant difference between groups was set at P <0.05 in
all analyses.
Results
Histologic wound scoring was conducted in a blinded
fashion using the dermal and epidermal regeneration
and the granulation tissue thickness, as described by
Kim and colleagues [26]. In both observations, the histo-
logical analysis of wound in the treated groups at days 8
and 15 showed that wounds displayed better epitheliali-
zation and more effective re-organization of the dermis
when compared with the control group (Fig. 1). When
compared between the treated groups, the TAc was
more efficient because it was possible to observe that
the complete remodeling of epidermis indicated the re-
gression of the lesions.
The evaluation of picrosirius staining demonstrated a
significant increase of collagen distribution in the TC
and TAc treatments compared with NC and TF groups.
Already on day 8, it was possible to observe the intense
reddish-yellow coloration of the collagen on TC and
TAc, indicates that especially these treatments have con-
tributed to the greater synthesis of these fibers (Fig. 2).
These observations were confirmed by the percentage of
area occupied by collagen fibers in each cut (Table 1).
Similar results were shown on biochemical analysis of
hydroxyproline levels, the basic constituent of collagen.
In the TC and TAc, the hydroxyproline content of dry
granulation tissue was significantly higher compared with
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NC and TF on day 8 (Table 2). These results suggest that
TC and TAc have strong wound healing potential.
The distribution of VEGF, which is one of the most
prominent angiogenic markers, was detected focally on the
dermis in both control and treated groups (Fig. 3). On day
8, the immunoreactivity was higher again in TC and TAc
and it was almost similar in the other groups. On the day
15, the distribution of VEGF was reduced in all treated
groups, but in TC and TAc there are less reduction, while a
low expression was seen in the NC. The histologic scores
of VEGF were statistically higher in TC and TAc, as shown
by the morphometry evaluation (Table 1).
The MMP-9 immunodistribution was similar to that of
VEGF, but was more intense in TC on day 8 (Fig. 4). At this
time, the reactivity of the MMP-9 was very increased in TC,
which strong labeling in all the tissue. As observed in the
VEGF study, the distribution of MMP-9 was reduced on the
day 15, and no differences were observed among the treated
groups. Comparing the different groups, MMP-9 histologic
scores were higher, particularly in TC on day 8 (Table 1).
Fig. 1 The histological evaluation of the skin flaps revealed by HE coloration (10x). Microscopic examination of TC and TAc groups indicated
regression of the lesions with better epithelialization (arrows) and more effective re-organization of the dermis (arrowhead) compared to the
NC and TF on 8th and 15th days after injury
Fig. 2 The evaluation of Picrosirius staining was made to recognize the total density of collagen. In each cut we analyzed the percentage of area
occupied by collagen fibers (reddish-yellow). The distribution of collagen was more intense mainly in TC and TAc groups (arrowhead) on 8th and
15th days after injury
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Discussion
In this study we propose for the first time that Acheflan®
possess higher therapeutic properties for wound healing
compared with TF and the effect was similar to TC. We
have demonstrated a better tissue formation and ree-
pithelialization, an increased distribution of collagen de-
position and significantly enhanced angiogenic marker
in the cutaneous injuries treated with TC and Acheflan®.
Skin wound healing is a complex physiological process
that involves multiple tissue and cell types, and usually
the wound progresses toward homeostasis through steps
involving inflammation, new tissue formation, and tissue
remodeling [28]. However, cutaneous wound healing is a
major interest for the public health sector because the
skin wounds affect a large number of patients, ser-
iously reducing their quality of life, requiring extended
hospitalization time, and accounts for a significant
amount of healthcare expenditures. Furthermore, the
scientific information about the potential effect of top-
ical agents on skin wound healing is limited [29].
Natural products have consistently been an important
source of therapeutic agents, therefore, we have evalu-
ated and compared topical effectiveness of collagenase
and fibrinolysin with phytomedicine Acheflan® on cu-
taneous injury.
Proteolytic enzymes have been used for wound de-
bridement for many years and the two most widely
used enzymes in the world are fibrinolysin/DNAse and
collagenase [30–33]. The collagenases, an enzymatic
debriding agent, act by degrading native helical collagen
fibrils [34]. Recently, Tallis and colleagues [33] showed
that collagenase ointment is tolerable and clinically
effective in achieving the removal of nonviable tissue in
the preparation of a healthy wound bed. In addition, a
study on infected accidental or surgical wounds, de-
bridement using fibrinolysin/ DNAse was reportedly
effective [35].
The main active constituent from the phytomedicine
Acheflan® is the oil from C. verbenacea, and its topical anti-
inflammatory and antinociceptive properties have already
been reported [18, 20, 23, 24]. Acheflan® was approved by
ANVISA in Brazil for the management of tendinopathy,
myofacial pain and trauma [4]. As far as we know, the
present work is the first study to focus on the effect of
Acheflan® in wound-healing model, and we have showed
that this phytomedicine had a role in the early wound heal-
ing processes. This effect displayed may be attributed to the
compounds isolated from C. verbenacea, sesquiterpene α-
humulene, which has revealed important anti-inflammatory
and antinociceptive properties [18, 20, 23, 24]. In addition,
previous data with Acheflan® cream showed that the α-
humulene is completely and fast absorbed when applied
topically [18].
Collagen has a well-established function in early wound
healing, and is the main component which strengthens
and supports extra cellular tissue, it is composed of amino
acid, hydroxyproline, which has been used as a biochem-
ical marker for tissue collagen [36, 37]. During the prolif-
erative phase, type III collagen is secreted by migrating
and proliferating fibroblasts, in and around the wound,
and this collagen is essential for creating the provisional
matrix during this phase. Type I collagen is also vital
during the maturation period and the most prevalent col-
lagen in uninjured skin [38]. Acheflan® has demonstrated
a significant increase in the hydroxyproline content and
Table 1 Histologic scores of collagen fibers, VEGF and MMP-9
in studied groups
Score (%) Group Day 0 Day 8 Day 15
Collagen fibers NC 60.3 ± 0.9 16.5 ± 1.4 59.9 ± 1.6
TC 60.3 ± 0.9 70.6 ± 1.2b, c 71.3 ± 1.6b, c
TF 60.3 ± 0.9 10.9 ± 1.6b 20.2 ± 1.4b
TAc 60.3 ± 0.9 68.9 ± 1.2b, c, d 67.7 ± 0.8b, c, d
P valuea 1.0 0.0001 0.0001
VEGF NC 1.5 ± 0.7 19.5 ± 2.1 2.6 ± 1.0
TC 1.5 ± 0.7 28.2 ± 1.5b, c 15.5 ± 1.3b, c
TF 1.5 ± 0.7 18.6 ± 0.8 12.0 ± 1.2b
TAc 1.5 ± 0.7 26.4 ± 1.8b, c, d 17.3 ± 1.1b, c, d
P valuea 1.0 0.0001 0.0001
MMP-9 NC 0.9 ± 0.8 10.2 ± 0.9 8.3 ± 1.1
TC 0.9 ± 0.8 47.8 ± 1.9b, c 10.8 ± 1.9b
TF 0.9 ± 0.8 11.9 ± 1.4b 10.9 ± 1.7b
TAc 0.9 ± 0.8 17.1 ± 0.8b, c, d 11.4 ± 0.6b
P valuea 1.0 0.0001 0.001
NC is negative control, TC is treated topically with Collagenase ointment, TF is
treated topically with Fibrinolysin and TAc is treated topically with
phytomedicine cream Acheflan. Day zero, 8th and 15th days after injury.
Values are mean ± standard deviations. aAnova test. bSignificant difference
when compared to NC group (Student t test, P < 0.05). cSignificant difference
when compared to TF group (Student t test, P < 0.05). dSignificant difference
when compared to TC group (Student t test, P < 0.05)
Table 2 Hydroxyproline levels in wound areas of the all
treatment groups
Group Day 0 Day 8 Day 15
NC 66 ± 8.3 67 ± 5.3 115 ± 2.7
TC 63 ± 1.9 86 ± 0.8b, c 122 ± 2.2
TF 59 ± 1.6 65 ± 1.3 120 ± 5.7
TAc 64 ± 2.7 107 ± 9.1b, c, d 127 ± 10.5
P valuea 0.087 0.0001 0.206
NC is negative control, TC is treated topically with Collagenase ointment, TF is
treated topically with Fibrinolysin and TAc is treated topically with phytomedicine
cream Acheflan. Day zero (n = 6), 8th (n = 3) and 15th (n = 3) days after injury.
Values are mean ± standard deviation from six animals in each group at day zero
and three animals in each group at 8th and 15th days after injury. aAnova test.
bSignificant difference when compared to NC group (Student t test, P < 0.05).
cSignificant difference when compared to TF group (Student t test, P < 0.05).
dSignificant difference when compared to TC group (Student t test, P < 0.05)
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collagen distribution of the granulation tissue after
8 days of injury indicating increased collagen turnover.
Similar results were reported with increase hydroxyproline
content around 2 times using excision wound model in
rats treated with extract of Punica granatum [13], Vitis
vinifera and Vaccinium macrocarpon [39], Allamanda
cathartica [40], Ixora coccinea [41] and Cleome viscose [6].
We used the immunohistochemical technique to ob-
serve the angiogenesis process through VEGF marking
in our experimental model. The VEGF is an angiogenic
peptide produced by endothelial cells, macrophages, and
many other cells, being an excellent marker for endothe-
lial cells [42]. In the present study, the TC and Acheflan®
exhibited the most intense distribution of VEGF in day
8th, indicating that this factor is mainly stimulated in
the early period of wound healing. This is in agreement
with the findings that many processes are involved in
the early period of wound healing and require action of
many factors to facilitate cell movement, granulation
tissue formation and angiogenesis [43–45].
On the other hand, changes in the ECM associated
with disease states may arrest progression of the
Fig. 3 Photomicrograph from immunostained with an antibody against VEGF in control and treated groups. The dermis in both groups exhibits
positive VEGF immunostaining (arrows); in TC and TAc the immunoreaction is higher, especially in day 8 (arrowheads)
Fig. 4 Immunohistochemical staining with MMP-9 in control and treated groups. The pattern of distribution of the MMP-9 staining is similar as
with the VEGF study, but anti–MMP-9 antibody immunoreactivity was more intense in TC on day 8 (arrows); on the day 15, the immunoreactions
were reduced and no differences were observed among the treated groups (arrowheads)
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sequence of stages, critical for wound healing. Exorbi-
tant production of a collagenous matrix can be also
questionable, resulting in cutaneous scarring that pro-
duce esthetic problem, functional damage, and discom-
fort [46]. In our study there is an interesting difference
between MMP-9 distribution in TC and Acheflan® on
day 8, with distribution in TC group extensively higher.
We know that MMP-9 have important function in the
angiogenesis process in dermal remodeling, but exacer-
bated levels seem to be negatively implicated in the
tissue degradation. In the same way, Kurtz and Oh [47]
also demonstrated that the aberrant ECM expression
may provide to pathologic wound responses.
We should consider that human skin differs from rat
skin, and the important difference is that human skin
heals preferentially by re-epithelialisation, while rat skin
heals mainly by wound contraction [14]. We acknowledge
the limitations for translational relevance of our experi-
mental study; however, skin lesions in animal models are
pertinent because provide significant contributions to ad-
vances in the treatment of skin wounds. Despite the limi-
tations of the experimental model, we have showed higher
topical effectiveness of Acheflan® on tissue formation, ree-
pithelialization, angiogenesis, collagen deposition under
cutaneous injury compared with TF.
Conclusion
In conclusion, our findings have demonstrated that Ache-
flan® accelerates wound healing in skin rat model, prob-
ably due to its involvement with the increase angiogenesis
and dermal remodeling.
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